All Photos(1)

Documents

Y0001426

Carvedilol for system suitability

Name: Carvedilol for system suitability
Brand: SIAL

European Pharmacopoeia (EP) Reference Standard

Synonym(s):

Carvedilol, 1-(9H-Carbazol-4-yloxy)-3-[[2-(2-methoxyphenoxy)ethyl]amino]-2-propanol, BM-14190

Sign Into View Organizational & Contract Pricing

All Photos(1)

About This Item

Empirical Formula (Hill Notation):

C₂₄H₂₆N₂O₄

CAS Number:

72956-09-3

Molecular Weight:

406.47

MDL number:

MFCD00864692

UNSPSC Code:

41116107

PubChem Substance ID:

329831421

NACRES:

NA.24

Recommended Products

Slide 1 of 10

1 of 10

Y0000103

Carvedilol impurity C

Y0001427

Carvedilol

Y0000714

Ritonavir

USP

1494909

Pantoprazole Related Compound A

USP

1012928

Alfuzosin System Suitability Mixture

Supelco

PHR2953

Carvedilol Related Compound C

B0200050

Baclofen impurity A

Sigma-Aldrich

R2886

Resorufin β-D-glucuronide sodium salt

Supelco

PHR1265

Carvedilol

USP

1642223

Sumatriptan succinate Related Compound C

grade

pharmaceutical primary standard

API family

carvedilol

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

SMILES string

OC(COC1=CC=CC2=C1C3=C(C=CC=C3)N2)CNCCOC4=CC=CC=C4OC

InChI

1S/C24H26N2O4/c1-28-21-10-4-5-11-22(21)29-14-13-25-15-17(27)16-30-23-12-6-9-20-24(23)18-7-2-3-8-19(18)26-20/h2-12,17,25-27H,13-16H2,1H3

InChI key

OGHNVEJMJSYVRP-UHFFFAOYSA-N

Gene Information

human ... ADRA1A(148) , ADRA1B(147) , ADRA1D(146) , ADRB1(153) , ADRB2(154) , ADRB3(155)

Looking for similar products? Visit Product Comparison Guide

Related Categories

Analytical Reference Materials for the Pharma Industry

Pharmacopeia & Metrological Institute Standards

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Carvedilol for system suitability EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Biochem/physiol Actions

Cavedilol is a non-selective β-adrenergic blocker with α1 blocking activity. Carvedilol is used specifically for the treatment of heart failure and high blood pressure. It has been shown to improve left ventricular ejection fraction and may reduce mortality.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

related product

Product No.

Description

Pricing

1096644

1096677

1096633

1096666

1096655

1096688

Carvedilol System Suitability Mixture, United States Pharmacopeia (USP) Reference Standard

PHR2434

PHR2435

PHR2952

PHR2953

pictograms

GHS09

hcodes

H411

pcodes

P273 - P391 - P501

Hazard Classifications

Aquatic Chronic 2

Storage Class

11 - Combustible Solids

wgk_germany

WGK 3

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Interaction of risk factors, comorbidities, and comedications with ischemia/reperfusion injury and cardioprotection by preconditioning, postconditioning, and remote conditioning.

Péter Ferdinandy et al.

Pharmacological reviews, 66(4), 1142-1174 (2014-09-28)

Pre-, post-, and remote conditioning of the myocardium are well described adaptive responses that markedly enhance the ability of the heart to withstand a prolonged ischemia/reperfusion insult and provide therapeutic paradigms for cardioprotection. Nevertheless, more than 25 years after the

Appropriate dose transition to a controlled-release formulation of carvedilol in patients with hypertension.

George L Bakris et al.

Reviews in cardiovascular medicine, 9(2), 96-105 (2008-07-29)

Few patients with hypertension meet recommended target blood pressure goals, and most hypertensive patients require at least 2 antihypertensive medications from different pharmacologic classes to adequately lower blood pressure. beta-Blockers are guideline-recommended for the treatment of hypertension with compelling indications.

Carvedilol therapy after cocaine-induced myocardial infarction in patients with asthma.

Timothy Self et al.

The American journal of the medical sciences, 342(1), 56-61 (2011-02-05)

Cocaine-induced myocardial infarction (MI) is well documented. Current literature recommends avoiding beta-blockers in the acute care setting, but after discharge from the hospital, benefits of beta-blocker use may outweigh risks in patients with recent MI resulting from cocaine use. Cardioselective

Clinical updates on carvedilol: a first choice beta-blocker in the treatment of cardiovascular diseases.

Subhashis Chakraborty et al.

Expert opinion on drug metabolism & toxicology, 6(2), 237-250 (2010-01-16)

Carvedilol, a non-selective beta-blocker, has recently drawn attention because of its therapeutic benefits over other prescribed analogues for the treatment of cardiovascular diseases (CVDs). The present review attempts to present the clinical efficacy of carvedilol in comparison to other available

Multicentre randomised controlled study comparing carvedilol with variceal band ligation in the prevention of variceal rebleeding.

Adrian J Stanley et al.

Journal of hepatology, 61(5), 1014-1019 (2014-06-24)

Rebleeding after an initial oesophageal variceal haemorrhage remains a significant problem despite therapy with band ligation, non-selective β-blockers or a combination of these. Carvedilol is a vasodilating non-selective β-blocker with alpha-1 receptor and calcium channel antagonism. A recent study has

View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service